AI assistant
HIKMA Pharmaceuticals PLC Director's Dealing 2021
4841_dirs_2021-03-15_3826dc2a-421c-4084-90b0-bfefb6dc5da5.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 2787S
Hikma Pharmaceuticals Plc
15 March 2021
Hikma Pharmaceuticals PLC - EIP B Vesting
LONDON, 15 March 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element B.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Said Darwazah |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Chairman |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. All Shares were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 61,666 |
| d) | Aggregated information - Volume - Price - Total |
61,666 £0.00 £0.00 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Siggi Olafsson
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Sigurdur Olafsson |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 35,513 Price(s): £22.057 Volume(s): 31,794 |
| d) | Aggregated information - Volume - Price - Total |
67,307 £22.057 £701,280.26 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Mazen Darwazah |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice Chairman |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. All Shares were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 42,572 |
| d) | Aggregated information - Volume - Price - Total |
42,572 £0.00 £0.00 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Riad Mishlawi |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. All Shares were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 32,027 |
| d) | Aggregated information - Volume - Price - Total |
32,027 £0.00 £0.00 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Majda Labadi |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. All Shares were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 17,091 |
| d) | Aggregated information - Volume - Price - Total |
17,091 £0.00 £0.00 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Bassam Kanaan |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. All Shares were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 27,193 |
| d) | Aggregated information - Volume - Price - Total |
27,193 £0.00 £0.00 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Khalid Nabilsi |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. All Shares were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 25,089 |
| d) | Aggregated information - Volume - Price - Total |
25,089 £0.00 £0.00 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Brian Hoffmann
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Brian Hoffmann |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 8,435 Price(s): £22.057 Volume(s): 7,552 |
| d) | Aggregated information - Volume - Price - Total |
15,987 £22.057 £166,574.46 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Susan Ringdal |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 7,626 Price(s): £22.057 Volume(s): 6,828 |
| d) | Aggregated information - Volume - Price - Total |
14,454 £22.057 £150,605.20 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Henriette Nielsen
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Henriette Nielsen |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained. |
| c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 4,627 Price(s): £22.057 Volume(s): 5,275 |
| d) | Aggregated information - Volume - Price - Total |
9,902 £22.057 £116,350.68 |
| e) | Date of the transaction | 12 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
15 March 2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBBGDXSDBDGBU